Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.35USD
25 May 2018
Change (% chg)

$0.10 (+3.08%)
Prev Close
$3.25
Open
$3.25
Day's High
$3.35
Day's Low
$3.25
Volume
14,776
Avg. Vol
51,036
52-wk High
$5.40
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Compugen Announces Exclusive License Agreement With Medimmune
Monday, 2 Apr 2018 08:43am EDT 

April 2 (Reuters) - Compugen Ltd ::SPECIFIC ANTIBODY PRODUCTS‍​.SEC FILING.CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES.  Full Article

Compugen Reports Q4 Loss Per Share Of $0.18
Wednesday, 21 Feb 2018 07:07am EST 

Feb 21 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.18.COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR.  Full Article

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 07:11am EST 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article

Compugen appoints Paul Sekhri as new board chairman
Wednesday, 2 Aug 2017 07:22am EDT 

Aug 2 (Reuters) - Compugen Ltd :Compugen welcomes paul sekhri as its new chairman of the board.Compugen ltd - sekhri will succeed martin gerstel, who announced his intention to retire from this role in february of this year.  Full Article

Compugen Q2 loss per share $0.18
Wednesday, 2 Aug 2017 07:20am EDT 

Aug 2 (Reuters) - Compugen Ltd :Compugen reports second quarter 2017 results.Q2 loss per share $0.18.Compugen ltd - ‍names paul sekhri as chairman of board effective october 2, 2017​.Compugen ltd - ‍as of june 30, 2017, cash and cash related accounts totaled $46.1 million, compared with $61.5 million as of december 31, 2016​.Compugen ltd - ‍now planning on filing an investigational new drug application for com701 towards end of q1 of 2018​.  Full Article

Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
Wednesday, 26 Jul 2017 07:09am EDT 

July 26 (Reuters) - Compugen Ltd ::Compugen discloses updates to collaborative activities with bayer in immuno-oncology.Compugen - agreement with Bayer AG involves research, development, commercialization of antibody-based therapeutics against cgen-15001t and cgen-15022.Compugen Ltd - it has been determined current collaboration will focus solely on cgen-15001t, all rights to cgen-15022 will be returned to Compugen.  Full Article

Compugen ‍anticipates delay of several months in submission of investigational new drug application for COM701​
Wednesday, 31 May 2017 07:00am EDT 

May 31 (Reuters) - Compugen Ltd ::Compugen provides update on com701 and upcoming presentations.Compugen Ltd - ‍anticipates a delay of several months in submission of an investigational new drug application (ind) for com701​.Compugen Ltd - ‍previously company had disclosed an expectation of IND filing for com701 in q4 of this year​.Compugen - informed by manufacturing service provider for com701 that batch of material manufactured for co's glp toxicity studies was contaminated.Compugen Ltd - "expect this delay may have a limited effect with respect to our on-going business development discussions for this program".Compugen - ‍contamination discovered during quality control procedures prior to release of affected batch and, as such, was not used in preclinical studies​.Compugen Ltd - ‍contamination of com701 batch has necessitated production of a new batch of material for execution of studies​.  Full Article

Compugen Q1 loss per share $0.17
Tuesday, 9 May 2017 07:13am EDT 

May 9 (Reuters) - Compugen Ltd : :Compugen reports first quarter 2017 results.Q1 loss per share $0.17.Q1 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Compugen files for mixed shelf of up to $200 million
Tuesday, 9 Aug 2016 06:32am EDT 

Compugen Ltd :Files for mixed shelf of upto $200 million - SEC filing.  Full Article

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)